Ariad Extends Three Tech Licensing Deals

Xconomy Boston — 

Ariad Pharmaceuticals (NASDAQ:ARIA), a Cambridge, MA-based developer of cancer drugs, said today it extended licenses to its cell-signaling regulation technology to three separate groups, all of which are using the technology for different purposes. Bellicum Pharmaceuticals of Houston, TX, is developing the technology for its experimental cancer vaccine and cell therapies; Washington, DC-based ReGenX Biosciences is using the technology to advance gene therapies; and Clontech Laboratories, a Mountain View, CA-based provider of research reagents, is licensing the technology for the research market. Some of the intellectual property for the technology comes from Harvard University and Stanford University. Ariad did not disclose specific financial figures from the licensing deals.